Silver Creek Pharmaceuticals is leveraging its innovative Smart Growth Factor™ technology to develop advanced therapies aimed at enhancing cell survival and healing damaged tissues. This platform focuses on creating fusion proteins that combine the beneficial properties of growth factors with engineered components to improve their therapeutic efficacy. The Smart Growth Factor™ platform consists of three key domains: a cytoprotective arm that activates pro-survival signaling pathways, a half-life extender to prolong the therapeutic presence of the growth factor in the body, and a targeting arm designed to bind specifically to cell surface markers associated with apoptosis. This targeted approach aims to optimize the delivery of therapeutic agents to injured cells while minimizing off-target effects.

The company's lead product, scp776, exemplifies the application of this technology. It is a first-in-class fusion protein that delivers insulin growth factor I (IGF1) directly to sites of injury, thereby enhancing the potential for recovery in conditions such as acute ischemic stroke, heart attacks, and kidney injuries. Preclinical studies have demonstrated scp776's ability to reduce scar size and improve functional outcomes, with promising results observed in non-human primate models for stroke. Currently, scp776 is undergoing a Phase II clinical trial to evaluate its safety and neuroprotective effects in patients experiencing acute ischemic stroke, highlighting Silver Creek's commitment to advancing its pipeline of life-changing therapies.

United States

Silver Creek Pharmaceuticals, Inc. is a Biotechnology company located in San Francisco, California, United States. We are harnessing the therapeutic potential of growth factors in a new class of biological molecules, to treat acute organ injuries.

Silver Creek Pharmaceuticals

Company Details